Back to top
more

scPharmaceuticals (SCPH)

(Delayed Data from NSDQ)

$5.52 USD

5.52
190,346

+0.35 (6.77%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $5.52 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -25.93% and 3.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -4.41% and 0.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 12.50% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 75% and 160.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

ImmunityBio (IBRX) delivered earnings and revenue surprises of 42.31% and 13.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Certara (CERT) delivered earnings and revenue surprises of 15.38% and 0.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vertex Pharmaceuticals (VRTX) Misses Q4 Earnings Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of -0.25% and 5.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -23.33% and 7.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of 6.78% and 53.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 35.56% and 103.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

TScan Therapeutics (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 16.67% and 5.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Liquidia Technologies (LQDA) Surges 11.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Liquidia Technologies (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Does scPharmaceuticals (SCPH) Have the Potential to Rally 291.9% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for scPharmaceuticals (SCPH) points to a 291.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 0% and 0.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 10.71% and 196.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of 33.33% and 23.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 20% and 6.17%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 46.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of -0.85% and 76.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 2.70% and 5.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for scPharmaceuticals, Inc. (SCPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.